A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

Summary

This clinical trial is evaluating a drug called AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC682 that can be given safely to participants * To evaluate the side effects of AC682 * To evaluate pharmacokinetics of AC682 * To evaluate the effectiveness of AC682

Timeline

Start

2021-11-12

Primary completion

2024-04-04

Completion

2024-04-04

Outcome

Outcome not reported

Stopped (Business): “Voluntarily terminate the study since the sponsor's development strategy was adjusted.”

Drugs

Indications